Effect of ANKASCIN 568-P Products Regulating Blood Lipid
ConditionHyperlipidemias
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorSunWay Biotech Co., LTD.
About this trial
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Eligibility criteria
Qualifiers
Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period).
A sane and communicative adult.
18≦BMI≦35.
Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs.
Disqualifiers
Triglyceride TG≧500 mg/dL.
Blood pressure value: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg.
Patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (SGPT), serum glutamate phenylacetate transaminase (SGOT) are more than 3 times the upper limit of normal or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml/min/1.73m2).
Pregnant or lactating women.
Trial design
Treatments tested in this trial
- ANKASCIN 568-P Red yeast rice capsules
- Placebo Capsules
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov